Brimonidine Tartrate Patent Expiration
Brimonidine Tartrate was first introduced by Allergan Inc
Brimonidine Tartrate Patents
Given below is the list of patents protecting Brimonidine Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mirvaso | US10201517 | Brimonidine gel compositions and methods of use | Jun 13, 2031 | Galderma Labs Lp |
| Mirvaso | US8053427 | Brimonidine gel composition | Jun 13, 2031 | Galderma Labs Lp |
| Mirvaso | US8163725 | Gel compositions and methods of use | Jun 13, 2031 | Galderma Labs Lp |
| Mirvaso | US8513247 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Mirvaso | US8513249 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Mirvaso | US9861631 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Mirvaso | US9861632 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Lumify | US8293742 | Preferential vasoconstriction compositions and methods of use | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify | US9259425 | Compositions and methods for eye whitening | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify Preservative Free | US8293742 | Preferential vasoconstriction compositions and methods of use | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify Preservative Free | US9259425 | Compositions and methods for eye whitening | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify | US11596600 | Vasoconstriction compositions and methods of use | Jul 27, 2029 | Bausch And Lomb Inc |
| Lumify | US11833245 | Vasoconstriction compositions and methods of use | Jul 27, 2029 | Bausch And Lomb Inc |
| Lumify Preservative Free | US11596600 | Vasoconstriction compositions and methods of use | Jul 27, 2029 | Bausch And Lomb Inc |
| Mirvaso | US7439241 | Compounds, formulations, and methods for treating or preventing rosacea | Aug 25, 2025 | Galderma Labs Lp |
| Qoliana | US7265117 | Topical brimonidine tartrate formulations that lack chlorine dioxide | Aug 19, 2025 | Sandoz |
| Mirvaso | US8231885 | Compounds, formulations, and methods for ameliorating telangiectasis | May 24, 2025 | Galderma Labs Lp |
| Mirvaso | US8410102 | Methods and compositions for treating or preventing erythema | May 24, 2025 | Galderma Labs Lp |
| Mirvaso | US8426410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | May 24, 2025 | Galderma Labs Lp |
| Mirvaso | US8859551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May 25, 2024
(Expired) | Galderma Labs Lp |
| Alphagan P |
US8858961 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Mar 02, 2024
(Expired) | Abbvie |
| Alphagan P | US8858961 | Compositions containing alpha-2-adrenergic agonist components |
Sep 02, 2023
(Expired) | Abbvie |
| Alphagan P |
US6641834 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 28, 2022
(Expired) | Abbvie |
| Alphagan P |
US6673337 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 26, 2022
(Expired) | Abbvie |
| Alphagan P |
US6627210 (Pediatric) | Compositions containing α-2-adrenergic agonist components |
Jan 18, 2022
(Expired) | Abbvie |
| Alphagan P |
US6562873 (Pediatric) | Compositions containing therapeutically active components having enhanced solubility |
Jan 10, 2022
(Expired) | Abbvie |
| Alphagan P |
US9295641 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 10, 2022
(Expired) | Abbvie |
| Alphagan P |
US9687443 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 10, 2022
(Expired) | Abbvie |
| Alphagan P | US6641834 | Compositions containing alpha-2-adrenergic agonist components |
Jul 28, 2021
(Expired) | Abbvie |
| Alphagan P | US6673337 | Compositions containing alpha-2-adrenergic agonist components |
Jul 26, 2021
(Expired) | Abbvie |
| Alphagan P | US6627210 | Compositions containing α-2-adrenergic agonist components |
Jul 18, 2021
(Expired) | Abbvie |
| Alphagan P | US10307368 | Compositions containing alpha-2-adrenergic agonist components |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P | US6562873 | Compositions containing therapeutically active components having enhanced solubility |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P | US9295641 | Compositions containing alpha-2-adrenergic agonist components |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P | US9687443 | Compositions containing alpha-2-adrenergic agonist components |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P |
US5424078 (Pediatric) | Aqueous ophthalmic formulations and methods for preserving same |
Dec 13, 2012
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brimonidine Tartrate's patents.
Latest Legal Activities on Brimonidine Tartrate's Patents
Given below is the list recent legal activities going on the following patents of Brimonidine Tartrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Feb, 2019 | US7265117 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Sep, 2007 | US7265117 |
| Recordation of Patent Grant Mailed Critical | 04 Sep, 2007 | US7265117 |
| Issue Notification Mailed Critical | 15 Aug, 2007 | US7265117 |
| Dispatch to FDC | 31 Jul, 2007 | US7265117 |
| Application Is Considered Ready for Issue Critical | 13 Jul, 2007 | US7265117 |
| Issue Fee Payment Received Critical | 09 Jul, 2007 | US7265117 |
| Issue Fee Payment Verified Critical | 09 Jul, 2007 | US7265117 |
| Mail Notice of Allowance Critical | 27 Jun, 2007 | US7265117 |
| Notice of Allowance Data Verification Completed Critical | 23 Jun, 2007 | US7265117 |
Brimonidine Tartrate's Family Patents
Explore Our Curated Drug Screens
Brimonidine Tartrate Generic API Manufacturers
Several generic applications have been filed for Brimonidine Tartrate. The first generic version for Brimonidine Tartrate was by Bausch And Lomb Pharmaceuticals Inc and was approved on May 28, 2003. And the latest generic version is by Lupin Ltd and was approved on Aug 26, 2024.
Given below is the list of companies who have filed for Brimonidine Tartrate generic, along with the locations of their manufacturing plants worldwide.
1. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 29, 2023 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Aug 1, 2023 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
2. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15% | solution/drops | Prescription | OPHTHALMIC | AT | Jan 31, 2022 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Dec 21, 2022 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
3. BAUSCH AND LOMB
Bausch And Lomb Pharmaceuticals Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Bausch And Lomb.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2%
(reference standard) | solution/drops | Prescription | OPHTHALMIC | AT | May 28, 2003 |
Manufacturing Plant Locations New
Bausch And Lomb's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Bausch And Lomb as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||
4. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.025% | solution/drops | Over the counter | OPHTHALMIC | N/A | Feb 16, 2024 |
5. INDOCO
Indoco Remedies Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Indoco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Nov 18, 2014 |
Manufacturing Plant Locations New
Indoco's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Indoco as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
6. LUPIN LTD
Lupin Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Aug 26, 2024 |
Manufacturing Plant Locations New
Lupin Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Lupin Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
7. MICRO LABS
Micro Labs Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Micro Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Nov 22, 2023 |
Manufacturing Plant Locations New
Micro Labs's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Micro Labs as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
8. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.33% BASE | gel | Prescription | TOPICAL | AB | Sep 23, 2021 |
Manufacturing Plant Locations New
Padagis Israel's manufacturing plants are situated in 1 country - Israel. Given below are the details of these plant locations as well as the firm names of Padagis Israel as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Israel |
| |||
9. RISING
Rising Pharma Holdings Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 14, 2006 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
10. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Jan 30, 2008 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Mar 4, 2024 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
11. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 11, 2019 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Aug 9, 2024 |
12. TEVA PARENTERAL
Teva Parenteral Medicines Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Teva Parenteral.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Discontinued | OPHTHALMIC | N/A | Sep 10, 2004 |
Manufacturing Plant Locations New
Teva Parenteral's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Teva Parenteral as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
13. UPSHER SMITH LABS
Upsher Smith Laboratories Llc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Upsher Smith Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15% | solution/drops | Prescription | OPHTHALMIC | AT | Jun 12, 2024 |